Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
89,600,000
-
Number of holders
-
119
-
Total 13F shares, excl. options
-
62,650,868
-
Shares change
-
+1,948,053
-
Total reported value, excl. options
-
$1,212,293,655
-
Value change
-
+$9,165,340
-
Put/Call ratio
-
13%
-
Number of buys
-
71
-
Number of sells
-
-53
-
Price
-
$19.35
Significant Holders of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) as of Q4 2022
155 filings reported holding VERV - Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2022.
Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) has 119 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 62,650,868 shares
of 89,600,000 outstanding shares and own 70% of the company stock.
Largest 10 shareholders include Alphabet Inc. (10,549,086 shares), FMR LLC (6,905,423 shares), STATE STREET CORP (4,471,049 shares), ARK Investment Management LLC (4,365,830 shares), VANGUARD GROUP INC (3,812,024 shares), BlackRock Inc. (3,594,074 shares), Casdin Capital, LLC (2,290,571 shares), FEDERATED HERMES, INC. (2,078,289 shares), ARCH Venture Management, LLC (2,008,809 shares), and T. Rowe Price Investment Management, Inc. (1,799,650 shares).
This table shows the top 119 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.